Five stocks stand out heading into Thursday, August 27, 2026, each carrying a bullish rating change issued on Wednesday, August 26. Nvidia's fiscal Q2 report late on August 26 will set the tone for the AI trade heading into the Federal Reserve's Jackson Hole symposium later in the week. The Federal Open Market Committee held the federal funds target range at 3.50% to 3.75% at its July 29 meeting, and the CME Group FedWatch tool still prices roughly an 80% probability that policy rates hold steady through the balance of 2026.
The five ideas below span biotech, energy midstream, food safety, semiconductors, and enterprise software. Each name received a specific thesis on Wednesday. These are editorial notes for consideration only, not personalized investment advice.
argenx SE (ARGX) – UBS Sees Broadening Autoimmune Franchise
Belgian-domiciled biotech argenx headlined Wednesday's upgrades when UBS analyst Xian Deng moved the stock from Neutral to Buy and raised his price target to $1,400 from $960. Deng argued that argenx's VYVGART franchise has broader autoimmune applicability than the market credits, with a widening pipeline in myasthenia gravis, immune thrombocytopenia, and additional IgG-mediated diseases. Wells Fargo's Derek Archila also lifted his target the same day to $1,415 from $1,350, keeping his Overweight rating.
Shares traded near $1,054.95 during Wednesday's session, up about 3.48% on the day, giving argenx a market capitalization near $65.6 billion. The 52-week range of $661.85 to $1,058.69 shows the stock making a fresh high on the UBS call. The trailing price-to-earnings multiple sits at 40.1.
Coverage is decidedly constructive. Eighteen analysts rate argenx a strong buy, with 17 bullish ratings and one neutral. The average price target of $1,165.78 implies roughly 11% upside from Wednesday's level, and Wells Fargo's $1,415 marks the high.
Risks: Franchise concentration in VYVGART remains meaningful. Any competitive read-through from rival FcRn inhibitors, safety data from ongoing trials, or slower-than-expected penetration in newer indications would test the thesis. Valuation is also elevated, and reimbursement pressures in international markets remain a persistent overhang.
DT Midstream (DTM) – Wolfe Turns Constructive on Gas Infrastructure
Natural gas pipeline operator DT Midstream was upgraded from Peer Perform to Outperform on Wednesday by Wolfe Research. The upgrade lands as U.S. natural gas demand growth from LNG export projects and AI-linked power generation continues to reshape midstream economics, with DTM's Haynesville and Appalachian assets positioned near key demand centers.
Shares traded near $132.66 during Wednesday's session, up about 4.67%, giving DT Midstream a market capitalization near $13.5 billion. The 52-week range of $100.73 to $152.88 leaves the stock roughly 13% below its high. The trailing price-to-earnings multiple stands at 29.1, and the dividend yield sits near 3%.
Consensus reads buy on 11 ratings, with five bullish, five neutral, and one bearish. The average price target of $153.09 implies roughly 15% upside from Wednesday's level, and Jefferies' Julien Dumoulin-Smith holds the high at $170.
Risks: Not everyone is convinced. Mizuho's Gabe Moreen maintained Neutral on July 31 with a $147 target, and Stifel's Selman Akyol downgraded to Hold in February. Regulatory delays on greenfield projects, natural gas basis differential compression, and interest-rate sensitivity remain the key operational and macro risks for the sector.
Neogen (NEOG) – Piper Sandler Sees Turnaround Taking Hold
Food and animal safety diagnostics specialist Neogen was upgraded from Neutral to Overweight on Wednesday by Piper Sandler analyst David Westenberg, who raised his price target to $14 from $13. Westenberg's thesis focuses on the company's stabilizing integration of the former 3M food safety business, with margin recovery and operational execution improving through the year.
Shares traded near $11.79 during Wednesday's session, up about 1.33%, giving Neogen a market capitalization near $2.57 billion. The 52-week range of $4.90 to $12.85 shows a stock that has more than doubled off the lows as the market began pricing in a turnaround.
Coverage on the name is thin but positive. Both Piper Sandler and Guggenheim's Subbu Nambi now sit at Buy, and Guggenheim's $12 target is on the low end while Piper's $14 marks the high. The average price target of $13 implies roughly 10% upside from Wednesday's level.
Risks: The turnaround is not fully de-risked. Neogen's trailing earnings remain negative, and any renewed weakness in genomics, veterinary diagnostics, or food processor demand could delay the operating margin recovery Westenberg is underwriting. Integration execution and free-cash-flow trajectory will remain the metrics investors track most closely on upcoming prints.
Lattice Semiconductor (LSCC) – Benchmark Adds a Fresh Buy
FPGA chipmaker Lattice Semiconductor was initiated with a Buy rating on Wednesday by Benchmark analyst David Williams. Williams' thesis: Lattice's low-power FPGA franchise is winning share in industrial and communications markets, and the company's newer mid-range devices open a materially larger addressable market as edge AI and networking demand accelerates.
Shares traded near $120.58 during Wednesday's session, up about 3.86%, giving Lattice a market capitalization near $16.5 billion. The 52-week range of $60.50 to $157.01 shows how sharply the stock has re-rated. The trailing price-to-earnings multiple is elevated at 474, reflecting the current earnings trough as the company invests in new product cycles.
Consensus is unanimously bullish. Eleven analysts rate Lattice a strong buy, all 11 bullish. The average price target of $155.91 implies roughly 29% upside from Wednesday's level, and KeyBanc's John Vinh holds the high at $180.
Risks: Cyclical exposure to industrial and communications end markets remains the biggest swing factor, and any renewed weakness in those verticals would pressure the mid-range ramp. Valuation on trailing earnings is demanding, and execution against Intel's Altera and larger FPGA rivals will be the operational test.
Atlassian (TEAM) – RBC Initiates With Fresh Outperform
Enterprise software name Atlassian was initiated with an Outperform rating on Wednesday by RBC Capital. RBC's thesis focuses on Atlassian's transition to a cloud-first model, expanding penetration in the enterprise segment via Jira and Confluence, and emerging monetization opportunities from AI-native features embedded in the platform.
Shares traded near $168.71 during Wednesday's session, up about 1.33%, giving Atlassian a market capitalization near $44.3 billion. The 52-week range of $56.01 to $184.00 shows how sharply the stock has recovered from spring lows. Trailing earnings remain negative on a GAAP basis.
Coverage is broadly bullish. Twenty analysts rate Atlassian a strong buy, with 17 bullish and three neutral. The average price target of $167.15 implies roughly flat return from Wednesday's level, but Truist's Miller Jump lifted his target to $185 on August 20 and Barclays' Raimo Lenschow sits at $172.
Risks: Not the entire panel is aligned. TD Cowen's Derrick Wood maintained Hold with an $85 target as of April, and net new seat additions in the mid-market remain a critical print-over-print variable. Cloud migration pace and AI-feature monetization will be the operational tests as investors weigh whether recent enterprise wins translate into durable ARR growth.
Found this helpful? Share it with others.